Francisco Esteva is an Oncology physician affiliated with Northwell Health. OpenAlex indexes 456 publications with 28,082 citations (h-index 80); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
160 E 34th St
New York, NY 100164744
Telephone
212-731-5657Registry record last updated 17 Mar 2014.
Clinical trials
- Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
Sponsor: M.D. Anderson Cancer Center
- The Impact of Obesity and Obesity Treatments on Breast Cancer
Sponsor: M.D. Anderson Cancer Center
- Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20252 payments$12,394openpaymentsdata.cms.gov ↗
- Stemline Therapeutics Inc.Program year20259 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
90.3%Aromatase Inhibitor52.9%Anastrozole76%Letrozole16%Exemestane8%Part D<11 patientsEstrogen Agonist/Antagonist28%Tamoxifen Citrate100%Part D≥45 patients+ 1 more class in this area
Nervous system
7.1%Phenothiazine5%Prochlorperazine Maleate100%Part D≥14 patientsGabapentinoids2.1%Gabapentin100%Part D<11 patientsCardiovascular
2.6%Antiarrhythmic2.6%Lidocaine-Prilocaine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
New England Journal of Medicine
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Gregersen
Northwell Health
Louis Kavoussi, MD
Northwell Health
David Eidelberg, MD
Northwell Health
Kenar Jhaveri, MD
Northwell Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”